Ipsen S.A. publishes its 2023 Consolidated Financial Statements

PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have...

CORRECTIVE STATEMENT Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026, published on July 9, 2026 Paris, July 22, 2026 This...